AR115311A1 - Anticuerpo biespecífico que específicamente se une a los subdominios iv y ii del dominio extracelular del her2 humano - Google Patents

Anticuerpo biespecífico que específicamente se une a los subdominios iv y ii del dominio extracelular del her2 humano

Info

Publication number
AR115311A1
AR115311A1 ARP190100823A ARP190100823A AR115311A1 AR 115311 A1 AR115311 A1 AR 115311A1 AR P190100823 A ARP190100823 A AR P190100823A AR P190100823 A ARP190100823 A AR P190100823A AR 115311 A1 AR115311 A1 AR 115311A1
Authority
AR
Argentina
Prior art keywords
extracellular domain
subdomines
specific antibody
human her2
antibody
Prior art date
Application number
ARP190100823A
Other languages
English (en)
Inventor
Aleksei Vladimirovich Cherkasov
Aleksandra Aleksandrovna Sozonova
Anna Valentinovna Evstrateva
Olga Viktorovna Nazarenko
Arina Vitalevna Anikina
Mariia Aleksandrovna Shchemeleva
Viktoriya Olegovna Shitikova
Elena Andreevna Krendeleva
Nina Grachyaevna Kharatian
Alexander Vladimirovich Prokofyev
Alexey Konstantinovich Misorin
Iakov Iurevich Ustiugov
Aleksei Aleksandrovich Aleksandrov
Pavel Andreevich Iakovlev
Mariia Igorevna Lomovskaia
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR115311A1 publication Critical patent/AR115311A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere al campo de la biotecnología y proporciona un anticuerpo biespecífico que específicamente se une al subdominio IV del dominio extracelular (ECD4) del HER2 humano (receptor 2 del factor de crecimiento epidérmico) y el subdominio II del dominio extracelular (ECD2) del HER2 humano. La presente también se refiere a ADN que codifica dicho anticuerpo, los vectores de expresión correspondientes y sus métodos de producción, así como a los métodos de tratamiento que utilizan dicho anticuerpo.
ARP190100823A 2018-03-29 2019-03-29 Anticuerpo biespecífico que específicamente se une a los subdominios iv y ii del dominio extracelular del her2 humano AR115311A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018111298A RU2018111298A (ru) 2018-03-29 2018-03-29 Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека

Publications (1)

Publication Number Publication Date
AR115311A1 true AR115311A1 (es) 2020-12-23

Family

ID=68058434

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100823A AR115311A1 (es) 2018-03-29 2019-03-29 Anticuerpo biespecífico que específicamente se une a los subdominios iv y ii del dominio extracelular del her2 humano

Country Status (5)

Country Link
AR (1) AR115311A1 (es)
RU (1) RU2018111298A (es)
TW (1) TW202003038A (es)
UY (1) UY38168A (es)
WO (1) WO2019190359A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013135588A1 (en) * 2012-03-16 2013-09-19 Covagen Ag Novel binding molecules with antitumoral activity
AU2014357292B2 (en) * 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2

Also Published As

Publication number Publication date
TW202003038A (zh) 2020-01-16
RU2018111298A (ru) 2019-10-01
WO2019190359A1 (ru) 2019-10-03
UY38168A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
CO2019013611A2 (es) Anticuerpos específicos para flt3 y sus usos
CL2017001090A1 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
EA201992670A1 (ru) Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CL2019002824A1 (es) Anticuerpos anti-lag3.
ECSP20075198A (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
PE20190392A1 (es) Antianticuerpos gprc5d, moleculas de union al antigeno biespecificas que se unen a gprc5d y cd3, y usos de estas
CL2017000711A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos.
CO2021009004A2 (es) Anticuerpos biespecíficos anti-cd28 x anti-cd22 y usos de estos
PE20170264A1 (es) Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso
CL2021001573A1 (es) Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos.
EA201890028A1 (ru) Антитело, связывающее cd3 человека
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
CR20190273A (es) Anticuerpos y polipéptidos dirigidos contra cd127
NI201400019A (es) Anticuerpo anti-alfabetatcr
AR103726A1 (es) Cristales de anticuerpos monoclonales anti-pd-1 humanos
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
AR113692A1 (es) Polipéptidos de fusión biespecíficos y sus métodos de uso
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
AR121881A1 (es) Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos
AR115311A1 (es) Anticuerpo biespecífico que específicamente se une a los subdominios iv y ii del dominio extracelular del her2 humano

Legal Events

Date Code Title Description
FB Suspension of granting procedure